Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) General Information
Description
Critical worldwide development, manufacturing and commercialization rights for drugs based in Basel, Switzerland.
Contact Information
Corporate Office
- Basel
- Switzerland
Corporate Office
- Basel
- Switzerland
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) FAQs
-
Where is Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) headquartered?
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) is headquartered in Basel, Switzerland.
-
What industry is Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) in?
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151)’s primary industry is Buildings and Property.
-
Is Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) a private or public company?
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) is a Private company.
-
What is the current valuation of Melodia Therapeutics (Commercial Rights for Drug Mdi-0151)?
The current valuation of Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) is .
-
What is Melodia Therapeutics (Commercial Rights for Drug Mdi-0151)’s current revenue?
The current revenue for Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) is .
-
Who are Melodia Therapeutics (Commercial Rights for Drug Mdi-0151)’s investors?
Melodia Therapeutics has invested in Melodia Therapeutics (Commercial Rights for Drug Mdi-0151).
-
When was Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) acquired?
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) was acquired on 21-Jun-2024.
-
Who acquired Melodia Therapeutics (Commercial Rights for Drug Mdi-0151)?
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) was acquired by Alivexis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process